Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
Emergent BioSolutions (NYSE: EBS) announced that its antiviral drug brincidofovir (TEMBEXA®) will be included in a clinical trial led by Africa CDC as part of the 'MpOx Study in Africa' (MOSA). The randomized double-blind placebo-controlled trial will evaluate the safety and efficacy of brincidofovir in treating mpox virus. Currently, there are no FDA-approved therapeutics for treating patients with mpox who are at risk of severe complications. While brincidofovir can be used for mpox in the U.S. under emergency Investigational New Drug protocol, this will be its first randomized controlled study for mpox treatment.
Emergent BioSolutions (NYSE: EBS) ha annunciato che il suo farmaco antivirale brincidofovir (TEMBEXA®) sarà incluso in uno studio clinico guidato dall'Africa CDC nell'ambito dello 'MpOx Study in Africa' (MOSA). Il trial randomizzato, in doppio cieco e controllato con placebo valuterà la sicurezza e l'efficacia del brincidofovir nel trattamento del virus mpox. Attualmente, non ci sono terapie approvate dalla FDA per trattare i pazienti con mpox che sono a rischio di gravi complicazioni. Sebbene il brincidofovir possa essere utilizzato per mpox negli Stati Uniti sotto un protocollo di emergenza Investigational New Drug, questo sarà il suo primo studio controllato randomizzato per il trattamento dell'mpox.
Emergent BioSolutions (NYSE: EBS) anunció que su medicamento antiviral brincidofovir (TEMBEXA®) será incluido en un ensayo clínico dirigido por Africa CDC como parte del 'MpOx Study in Africa' (MOSA). El ensayo aleatorizado, doble ciego y controlado con placebo evaluará la seguridad y eficacia del brincidofovir en el tratamiento del virus mpox. Actualmente, no hay terapias aprobadas por la FDA para tratar a pacientes con mpox que están en riesgo de complicaciones severas. Si bien el brincidofovir puede usarse para mpox en EE. UU. bajo un protocolo de Emergencia de Nuevo Medicamento en Investigación, este será su primer estudio controlado aleatorio para el tratamiento de mpox.
Emergent BioSolutions (NYSE: EBS)는 항바이러스 약물 brincidofovir (TEMBEXA®)가 아프리카 CDC 주도로 진행되는 'MpOx Study in Africa' (MOSA) 임상 시험에 포함된다고 발표했습니다. 무작위 이중 맹검 위약 대조 시험은 mpox 바이러스 치료를 위한 brincidofovir의 안전성과 효과를 평가할 예정입니다. 현재, 중증 합병증 위험이 있는 mpox 환자를 치료하기 위한 FDA 승인 치료제가 없습니다. 브린시도포비르는 미국에서 긴급 조사 신약 프로토콜 하에 mpox에 사용할 수 있지만, 이는 mpox 치료를 위한 첫 번째 무작위 대조 연구입니다.
Emergent BioSolutions (NYSE: EBS) a annoncé que son médicament antiviral brincidofovir (TEMBEXA®) sera inclus dans un essai clinique dirigé par Africa CDC dans le cadre de l'étude 'MpOx Study in Africa' (MOSA). L'essai randomisé, en double aveugle et contrôlé par placebo évaluera la sécurité et l'efficacité du brincidofovir dans le traitement du virus mpox. Actuellement, il n'existe pas de thérapies approuvées par la FDA pour traiter les patients atteints de mpox qui sont à risque de complications graves. Bien que le brincidofovir puisse être utilisé pour le mpox aux États-Unis dans le cadre d'un protocole d'urgence pour un médicament expérimental, ce sera sa première étude contrôlée randomisée pour le traitement du mpox.
Emergent BioSolutions (NYSE: EBS) gab bekannt, dass das antivirale Medikament brincidofovir (TEMBEXA®) Teil einer klinischen Studie sein wird, die von der Africa CDC im Rahmen der 'MpOx Study in Africa' (MOSA) geleitet wird. Die randomisierte, doppelt blinde placebo-kontrollierte Studie wird die Sicherheit und Wirksamkeit von brincidofovir bei der Behandlung des mpox-Virus evaluieren. Derzeit gibt es keine von der FDA zugelassenen Therapeutika zur Behandlung von mpox-Patienten, die ein hohes Risiko für schwere Komplikationen haben. Während brincidofovir in den USA im Rahmen eines Notfall-Protokolls für investigational New Drug zur Behandlung von mpox eingesetzt werden kann, wird dies die erste randomisierte kontrollierte Studie zur Behandlung von mpox sein.
- First randomized controlled trial for brincidofovir in mpox treatment
- Potential to address unmet medical need with no current FDA-approved therapeutics for severe mpox
- None.
Insights
The initiation of a randomized double-blind placebo-controlled trial for brincidofovir (TEMBEXA®) in Africa represents a significant clinical development for Emergent BioSolutions. This study is particularly noteworthy because:
- It's the first controlled trial evaluating brincidofovir for mpox treatment, addressing an unmet medical need with no FDA-approved therapeutics for severe cases
- The trial's timing aligns with WHO's recent emergency declaration regarding mpox in Africa
- Success could lead to expanded market opportunities and regulatory approvals
The collaboration with Africa CDC and PANTHER enhances the study's credibility and could accelerate market access in Africa if results are positive. However, investors should note that clinical trials carry inherent risks and success isn't guaranteed.
This development opens significant market potential for Emergent BioSolutions in the African healthcare sector. With mpox declared a continental security emergency by Africa CDC, successful trial results could position TEMBEXA® as a first-line treatment across Africa. The current market opportunity is substantial given:
- No existing FDA-approved treatments for severe mpox cases
- Growing public health concern in multiple African countries
- Potential for emergency use authorizations in additional markets
However, market penetration will depend on pricing strategies suitable for African markets and government procurement policies. The WHO emergency declaration could facilitate faster regulatory pathways and market access.
- PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa’ (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial.
“We applaud Africa CDC and PANTHER for the launch of the ‘MpOx Study in Africa’ (MOSA), an important step in advancing research for brincidofovir, and are proud to support the trial with our brincidofovir antiviral treatment,” said Joe Papa, president and CEO, Emergent BioSolutions. “Emergent is committed to working with partners around the world to study and produce vaccines and treatments to address all orthopoxviruses, including mpox and smallpox.”
Brincidofovir is an antiviral medical countermeasure that is part of Emergent’s product portfolio. There are currently no therapeutics approved by the FDA to treat patients infected by mpox virus who are at risk of severe complications. While brincidofovir treatment is available to be used for mpox in the U.S. under emergency Investigational New Drug protocol, it has not yet been evaluated in any randomized double-blind placebo-controlled studies for mpox.
On August 13, Africa CDC declared mpox a public health emergency of continental security, which was followed by a statement from World Health Organization’s Director-General declaring that the upsurge of mpox in the DRC and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations (2005).
About the clinical trial: The study MOSA (MpOx Study in Africa) is a pan-African, double-blind, platform adaptive trial assessing treatments for patients diagnosed with mpox virus. Inclusion criteria are children, adults with mucosal lesions or PLWHIV. It is sponsored by PANTHER as part of the MPX-RESPONSE Project that has received funding from the European Union’s Horizon Europe Research and Innovation programme under grant agreement 101115188. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries.
Please read full Prescribing Information for TEMBEXA® for additional safety information here.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we help protect public health, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the any future procurements to supply brincidofovir (brand name TEMBEXA®), are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on Emergent’s current intentions, beliefs, and expectations regarding future events. Emergent cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Emergent’s expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Emergent does not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause Emergent’s actual results to differ materially from those indicated by any forward-looking statements.
Readers should consider this cautionary statement, as well as the risk factors identified in Emergent’s periodic reports filed with the U.S. Securities and Exchange Commission when evaluating Emergent’s forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
What is the purpose of Emergent BioSolutions' (EBS) MOSA clinical trial?
Is Emergent BioSolutions' (EBS) brincidofovir FDA-approved for mpox treatment?